Treatment Naïve Clinical Research Trials

Current clinical trials that are available for treatment-naïve or newly diagnosed AIDS/HIV patients. Individual requirements and treatments for each study differ.

True Prevalence 

The True Prevalence study will use current or new genotype testing to detect low level resistance, particularly to NNRTIs that may cause treatment failure.

Requirements for this study include:

• Naïve subjects about to initiate NNRTI and NRTI ART (no PI), baseline genotype shows no NRTI or NNRTI resistance 
• Viral load > 25,000 

Treatment will include:

• Observational 

To become involved, contact Brian Lane:

• Phone: 919-668-0166
• E-mail: brian.lane@mc.duke.edu

A5240 - HPV Vaccine Study

Safety and immune response to HPV vaccine in HIV+ females.

Requirements for this study include:

• HIV+ female, aged 18-45
• ART naïve, or experienced

Treatment will include:

• All participants will be vaccinated with the HPV recombinant vaccine (Gardasil) by injection

To participate in this study, contact Joan Riddle, RN:

• Phone: 919-668-0175
• E-mail: riddl007@mc.duke.edu
• For more information about this study follow this link to clinicaltrials.gov Web site:
  http://www.clinicaltrials.gov/ct2/show/NCT00604175?term=HIV&recr=Open&id=actg+5240&age=1&fund=0&rank=1 

Structured Treatment Interruption

This study will compare the effect of intermittent versus terminal treatment interruption for subjects started on anti-retroviral therapy (ART) during acute infection.

Requirements for this study include:

• Start of ART within 60 days of diagnosis with acute infection
• Six months of ART prior to study entry
• Viral load <200 copies for 90 days prior to study entry

Medications are not provided by study.

To become involved, please contact Kara McGee

• Phone: 919-668-0242
• E-mail: mcgee018@mc.duke.edu